{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:39Z","timestamp":1794047499212,"version":"4.8.0"},"reference-count":49,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"9","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Plasma cell leukemia (PCL) is a rare and aggressive plasma cell disorder with a short survival duration despite the use of novel therapeutics. PCL remains an understudied disease for which there is no current standard of care treatment. Knowledge on optimal novel drug sequencing, including the role and timing of hematopoietic stem cell transplant as primary and salvage therapy is needed. We conducted a large retrospective analysis of 153 PCL patients, using the new definition of \u22655% circulating plasma cells, including clinical features and treatment outcomes across seven academic centers in the United States. This is, to the best of our knowledge, the largest multicenter study conducted in the US of this rare disease. Disease presentation, clinical and genetic characteristics, and treatment patterns of 93 patients with primary PCL and 57 with secondary PCL are described. Additionally, associations between patient characteristics and mortality were investigated using Cox proportional hazards regression models. Secondary PCL was associated with a worse prognosis, with a median overall survival of 3.2 months compared to 36.6 months for primary PCL (P&lt;0.001). Receipt of a transplant was associated with a survival advantage in both primary PCL (Hazard Ratio [HR] 0.16, P&lt;0.001) and secondary PCL (HR 0.20, P=0.001). No significant difference in outcomes was observed between proteasome inhibitor-based triplet regimens and the VTD-PACE like regimen. The presence of extramedullary disease and high-risk cytogenetics was not associated with survival in the primary PCL group.<\/jats:p>","DOI":"10.3324\/haematol.2024.287158","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T03:08:26Z","timestamp":1744859306000},"page":"2129-2138","source":"Crossref","is-referenced-by-count":5,"title":["Outcomes and treatment patterns in primary and secondary plasma cell leukemia: insights from a large US cohort study"],"prefix":"10.3324","volume":"110","author":[{"given":"Shagun","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supriya","family":"Peshin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy C.","family":"Wertheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iloabueke","family":"Chineke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas W.","family":"Sborov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Liedtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Okoniewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Wazir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Nadeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levanto G.","family":"Schachter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"DeGraaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria A.","family":"Vardell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Coffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisstina","family":"Gowin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"key":"78873","doi-asserted-by":"crossref","unstructured":"Ramsingh G, Mehan P, Luo J, Vij R, Morgensztern D. Primary plasma cell leukemia: a Surveillance, Epidemiology, and End Results database analysis between 1973 and 2004. Cancer. 2009; 115(24):5734-5739.","DOI":"10.1002\/cncr.24700"},{"key":"78874","doi-asserted-by":"crossref","unstructured":"International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003; 121(5):749-757.","DOI":"10.1046\/j.1365-2141.2003.04355.x"},{"key":"78875","doi-asserted-by":"crossref","unstructured":"Tiedemann RE, Gonzalez-Paz N, Kyle RA. Genetic aberrations and survival in plasma cell leukemia. Leukemia. 2008; 22(5):1044-1052.","DOI":"10.1038\/leu.2008.4"},{"key":"78876","doi-asserted-by":"crossref","unstructured":"Papadhimitriou SI, Terpos E, Liapis K. The cytogenetic profile of primary and secondary plasma cell leukemia: etiopathogenetic perspectives, prognostic impact and clinical relevance to newly diagnosed multiple myeloma with differential circulating clonal plasma cells. Biomedicines. 2022; 10(2):209.","DOI":"10.3390\/biomedicines10020209"},{"key":"78877","doi-asserted-by":"crossref","unstructured":"Kyle RA, Maldonado JE, Bayrd ED. Plasma cell leukemia. Report on 17 cases. Arch Intern Med. 1974; 133(5):813-818.","DOI":"10.1001\/archinte.133.5.813"},{"key":"78878","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez de Larrea C, Kyle R, Rosi\u00f1ol L. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer J. 2021; 11(12):192.","DOI":"10.1038\/s41408-021-00587-0"},{"key":"78879","doi-asserted-by":"crossref","unstructured":"Gonsalves WI, Rajkumar SV, Go RS. Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood. 2014; 124(6):907-912.","DOI":"10.1182\/blood-2014-03-565051"},{"key":"78880","doi-asserted-by":"crossref","unstructured":"Li C, Cao W, Que Y. A phase I study of anti-BCMA CAR T cell therapy in relapsed\/refractory multiple myeloma and plasma cell leukemia. Clin Transl Med. 2021; 11(3):e346.","DOI":"10.1002\/ctm2.346"},{"key":"78881","doi-asserted-by":"crossref","unstructured":"Parrondo RD, Moustafa MA, Reeder C. Efficacy of daratumumab-based regimens for the treatment of plasma cell leukemia. Clin Lymphoma Myeloma Leuk. 2021; 21(5):355-360.","DOI":"10.1016\/j.clml.2021.01.002"},{"key":"78882","doi-asserted-by":"crossref","unstructured":"Li AY, Kamangar F, Holtzman NG. A clinical perspective on plasma cell leukemia: a single-center experience. Cancers (Basel). 2024; 16(11):2149.","DOI":"10.3390\/cancers16112149"},{"key":"78883","doi-asserted-by":"crossref","unstructured":"Tessier C, LeBlanc R, Roy J. Poor outcome despite modern treatments: a retrospective study of 99 patients with primary and secondary plasma cell leukemia. Cancer Med. 2024; 13(17):e70192.","DOI":"10.1002\/cam4.70192"},{"key":"78884","doi-asserted-by":"crossref","unstructured":"Noel P, Kyle RA. Plasma cell leukemia: an evaluation of response to therapy. Am J Med. 1987; 83(6):1062-1068.","DOI":"10.1016\/0002-9343(87)90942-9"},{"key":"78885","doi-asserted-by":"crossref","unstructured":"Sonneveld P, Avet-Loiseau H, Lonial S. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016; 127(24):2955-2962.","DOI":"10.1182\/blood-2016-01-631200"},{"key":"78886","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Sanz R, Orf\u00e3o A, Gonz\u00e1lez M. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood. 1999; 93(3):1032-1037.","DOI":"10.1182\/blood.V93.3.1032.403a15_1032_1037"},{"key":"78887","doi-asserted-by":"crossref","unstructured":"Jung SH, Lee JJ, Kim K. The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160). Oncotarget. 2017; 8(45):79517-79526.","DOI":"10.18632\/oncotarget.18535"},{"key":"78888","doi-asserted-by":"crossref","unstructured":"Jurczyszyn A, Castillo JJ, Avivi I. Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. Leuk Lymphoma. 2019; 60(1):118-123.","DOI":"10.1080\/10428194.2018.1473574"},{"key":"78889","doi-asserted-by":"crossref","unstructured":"Katodritou E, Terpos E, Delimpasi S. Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group. Blood Cancer J. 2018; 8(3):31.","DOI":"10.1038\/s41408-018-0059-6"},{"key":"78890","doi-asserted-by":"crossref","unstructured":"Pagano L, Valentini CG, De Stefano V. Primary plasma cell leukemia: a retrospective multicenter study of 73 patients. Ann Oncol. 2011; 22(7):1628-1635.","DOI":"10.1093\/annonc\/mdq646"},{"key":"78891","doi-asserted-by":"crossref","unstructured":"Gowda L, Shah M, Badar I. Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs. Bone Marrow Transplant. 2019; 54(7):1089-1093.","DOI":"10.1038\/s41409-018-0392-1"},{"key":"78892","doi-asserted-by":"crossref","unstructured":"Royer B, Minvielle S, Diouf M. Bortezomib, doxorubicin, cyclophosphamide, dexamethasone induction followed by stem cell transplantation for primary plasma cell leukemia: a prospective phase II study of the Intergroupe Francophone du My\u00e9lome. J Clin Oncol. 2016; 34(18):2125-2132.","DOI":"10.1200\/JCO.2015.63.1929"},{"key":"78893","doi-asserted-by":"crossref","unstructured":"Katodritou E, Terpos E, Kelaidi C. Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: analysis of the Greek myeloma study group. Am J Hematol. 2014; 89(2):145-150.","DOI":"10.1002\/ajh.23600"},{"key":"78894","doi-asserted-by":"crossref","unstructured":"Lebovic D, Zhang L, Alsina M. Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experience. Clin Lymphoma Myeloma Leuk. 2011; 11(6):507-511.","DOI":"10.1016\/j.clml.2011.06.010"},{"key":"78895","doi-asserted-by":"crossref","unstructured":"Lawless S, Iacobelli S, Knelange NS. Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modeling. Haematologica. 2023; 108(4):1105-1114.","DOI":"10.3324\/haematol.2021.280568"},{"key":"78896","doi-asserted-by":"crossref","unstructured":"Mahindra A, Kalaycio ME, Vela-Ojeda J. Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research. Leukemia. 2012; 26(5):1091-1097.","DOI":"10.1038\/leu.2011.312"},{"key":"78897","doi-asserted-by":"crossref","unstructured":"Dhakal B, Patel S, Girnius S. Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia. 2020; 34(12):3338-3347.","DOI":"10.1038\/s41375-020-0830-0"},{"key":"78898","doi-asserted-by":"crossref","unstructured":"Atas U, Salim O, Iltar U. Survival outcomes of patients with primary plasma cell leukemia in the era of proteasome inhibitors and immunomodulatory agents: a real-life multicenter analysis. Turk J Haematol. 2024; 41(4):225-235.","DOI":"10.4274\/tjh.galenos.2024.2024.0450"},{"key":"78899","doi-asserted-by":"crossref","unstructured":"Katodritou E, Kastritis E, Dalampira D. Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab-based quadruplets: a multicenter study by the Greek myeloma study group. Am J Hematol. 2023; 98(5):730-738.","DOI":"10.1002\/ajh.26891"},{"key":"78900","doi-asserted-by":"crossref","unstructured":"Katodritou E, Verrou E, Gastari V, Hadjiaggelidou C, Terpos E, Zervas K. Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?. Leuk Res. 2008; 32(7):1153-1156.","DOI":"10.1016\/j.leukres.2007.11.010"},{"key":"78901","doi-asserted-by":"crossref","unstructured":"Martiniani R, Di Loreto V, Di Sano C, Lombardo A, Liberati AM. Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma. Adv Hematol. 2012; 2012:842945.","DOI":"10.1155\/2012\/842945"},{"key":"78902","doi-asserted-by":"crossref","unstructured":"Shalaby K, Azad F, Parker S. Clinical characteristics and survival outcomes of patients with primary and secondary plasma cell leukemia according to the 2021 definition: a single center retrospective study. Clin Lymphoma Myeloma Leuk. 2025; 25(1):67-75.","DOI":"10.1016\/j.clml.2024.10.014"},{"key":"78903","doi-asserted-by":"crossref","unstructured":"Wang H, Zhou H, Zhang Z, Geng C, Chen W. Bortezomib-based regimens improve the outcome of patients with primary or secondary plasma cell leukemia: a retrospective cohort study. Turk J Haematol. 2020; 37(2):91-97.","DOI":"10.4274\/tjh.galenos.2019.2019.0254"},{"key":"78904","doi-asserted-by":"crossref","unstructured":"Skerget S, Penaherrera D, Mikhael J, Keats JJ. High-risk gene expression subtype provides molecular basis for different clinical presentation of primary and secondary plasma cell leukemia. Blood. 2021; 138(Suppl 1):726.","DOI":"10.1182\/blood-2021-148138"},{"key":"78905","doi-asserted-by":"crossref","unstructured":"Sica S, Chiusolo P, Salutari P. Long-lasting complete remission in plasma cell leukemia after aggressive chemotherapy and CD34-selected autologous peripheral blood progenitor cell transplant: molecular follow-up of minimal residual disease. Bone Marrow Transplant. 1998; 22(8):823-825.","DOI":"10.1038\/sj.bmt.1701420"},{"key":"78906","doi-asserted-by":"crossref","unstructured":"Yeh KH, Lin MT, Tang JL, Yang CH, Tsay W, Chen YC. Long-term disease-free survival after autologous bone marrow transplantation in a primary plasma cell leukaemia: detection of minimal residual disease in the transplant marrow by third-complementarity-determining region-specific probes. Br J Haematol. 1995; 89(4):914-916.","DOI":"10.1111\/j.1365-2141.1995.tb08437.x"},{"key":"78907","doi-asserted-by":"crossref","unstructured":"Kaiser MF, Hall A, Walker K. Depth of response and minimal residual disease status in ultra high-risk multiple myeloma and plasma cell leukemia treated with daratumumab, bortezomib, lenalidomide, cyclophosphamide and dexamethasone (Dara-CVRd): results of the UK optimum\/ MUKnine trial. J Clin Oncol. 2021; 39:8001.","DOI":"10.1200\/JCO.2021.39.15_suppl.8001"},{"key":"78908","doi-asserted-by":"crossref","unstructured":"Blum A, Haussmann K, Streitz M. Standardized assay for assessment of minimal residual disease in blood, bone marrow and apheresis from patients with plasma cell myeloma. Sci Rep. 2019; 9(1):2922.","DOI":"10.1038\/s41598-019-39631-2"},{"key":"78909","doi-asserted-by":"crossref","unstructured":"Avet-Loiseau H, Daviet A, Brigaudeau C. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du My\u00e9lome and the Groupe Fran\u00e7ais de Cytog\u00e9n\u00e9tique H\u00e9matologique. Blood. 2001; 97(3):822-825.","DOI":"10.1182\/blood.V97.3.822"},{"key":"78910","doi-asserted-by":"crossref","unstructured":"Chang H, Qi X, Yeung J, Reece D, Xu W, Patterson B. Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia. Leuk Res. 2009; 33(2):259-262.","DOI":"10.1016\/j.leukres.2008.06.027"},{"key":"78911","doi-asserted-by":"crossref","unstructured":"Cazaubiel T, Leleu X, Perrot A. Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features. Blood. 2022; 139(17):2666-2672.","DOI":"10.1182\/blood.2021014968"},{"key":"78912","doi-asserted-by":"crossref","unstructured":"Deng J, Qin X, Ma G. Development of a clinical prognostic model for primary plasma cell leukemia patients treated with novel agents: a multicenter retrospective cohort study. Ann Hematol. 2024; 103(9):3691-3699.","DOI":"10.1007\/s00277-024-05862-1"},{"key":"78913","doi-asserted-by":"crossref","unstructured":"Schinke C, Boyle EM, Ashby C. Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns. Blood Cancer J. 2020; 10(6):70.","DOI":"10.1038\/s41408-020-0336-z"},{"key":"78914","doi-asserted-by":"crossref","unstructured":"Usmani SZ, Nair B, Qu P. Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols. Leukemia. 2012; 26(11):2398-2405.","DOI":"10.1038\/leu.2012.107"},{"key":"78915","doi-asserted-by":"crossref","unstructured":"Kraj M, Kope\u0107-Szl\u0119zak J, Pog\u0142\u00f3d R, Kruk B. Flow cytometric immunophenotypic characteristics of 36 cases of plasma cell leukemia. Leuk Res. 2011; 35(2):169-176.","DOI":"10.1016\/j.leukres.2010.04.021"},{"key":"78916","doi-asserted-by":"crossref","unstructured":"Jimenez-Zepeda VH, Neme-Yunes Y, Braggio E. Chromosome abnormalities defined by conventional cytogenetics in plasma cell leukemia: what have we learned about its biology?. Eur J Haematol. 2011; 87(1):20-27.","DOI":"10.1111\/j.1600-0609.2011.01629.x"},{"key":"78917","doi-asserted-by":"crossref","unstructured":"DeGraaff D, Coffey DG. Spinal disease predicts CNS involvement in patients with plasma cell leukemia. Blood. 2021; 138(Suppl 1):4746.","DOI":"10.1182\/blood-2021-154537"},{"key":"78918","doi-asserted-by":"crossref","unstructured":"Charalampous C, Doucette K, Chappell A, Vesole DH. Venetoclax-based induction therapy for primary plasma cell leukemia with high BCL-2 expression. Leuk Lymphoma. 2024; 65(12):1901-1904.","DOI":"10.1080\/10428194.2024.2381647"},{"key":"78919","doi-asserted-by":"crossref","unstructured":"Roy T, An JB, Doucette K, Chappell AM, Vesole DH. Venetoclax in upfront induction therapy for primary plasma cell leukemia with t(11;14) or BCL2 expression. Leuk Lymphoma. 2022; 63(3):759-761.","DOI":"10.1080\/10428194.2021.2010065"},{"key":"78920","doi-asserted-by":"crossref","unstructured":"Elsabah H, Ghasoub R, El Omri H, Benkhadra M, Cherif H, Taha RY. Venetoclax in the treatment of secondary plasma cell leukemia with translocation t(11;14): a case report and literature review. Front Oncol. 2024; 14:1390747.","DOI":"10.3389\/fonc.2024.1390747"},{"key":"78921","doi-asserted-by":"crossref","unstructured":"Garfall AL, Stadtmauer EA, Hwang WT. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight. 2018; 3(8):120505.","DOI":"10.1172\/jci.insight.120505"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/12031\/78287","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/12031\/78740","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/12031\/78287","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:08:35Z","timestamp":1794046115000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/12031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":49,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.287158","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,17]]}}}